# Localised penile cancer (organ-confined, node-negative)

Source: https://onco.cc/cancers/localised-penile-cancer/  
OnCo record `localised-penile-cancer` (Cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Localised penile cancer is squamous cell cancer confined to the penis with no spread to the groin lymph nodes, and the aim of treatment is to remove the tumour while keeping as much of the penis as possible. Precancer and small tumours are treated with creams, laser or glans-sparing surgery, and the groin nodes are checked by sentinel node biopsy or surveillance rather than removed wholesale.

## Summary

Penile squamous cell carcinoma begins on the glans, the inner foreskin or the coronal sulcus, in roughly a third to a half of cases driven by HPV (basaloid and warty types, p16 positive) and otherwise by chronic inflammation, lichen sclerosus and phimosis (usual, verrucous and sarcomatoid types, often TP53 mutant). Penile intraepithelial neoplasia (PeIN) is its precursor. The 2023 EAU-ASCO guideline places organ preservation at the centre of care: PeIN and superficial tumours are treated with topical fluorouracil or imiquimod, laser ablation, circumcision or glans resurfacing; T1 and T2 tumours with glansectomy or partial penectomy with a margin of a few millimetres, which oncological series have shown to be safe; and brachytherapy is an alternative for small distal tumours. Total penectomy is kept for large or proximal tumours.

What decides survival is the groin. Palpably normal nodes still hide metastases in about a fifth of patients with tumours of intermediate or high risk (T1 with grade 2 or higher, lymphovascular invasion, or any T2 or worse), so the guideline recommends dynamic sentinel node biopsy for those patients rather than surveillance, and surveillance only for low-risk tumours; if the sentinel node is positive the patient moves into node-positive management. Circumcision and HPV vaccination prevent much of the disease, and the rarity of penile cancer means that referral to a specialised centre, as required in the United Kingdom since 2002, improves organ preservation and survival.

## Fields

- Kind: Cancer
- Last checked: 2026-09-18
- Also known as: Early penile squamous cell carcinoma; Organ-confined penile cancer; Penile intraepithelial neoplasia and T1 to T2 penile cancer; cN0 penile cancer
- Tags: subtype-page; genitourinary
- Group: genitourinary
- Burden: Most penile cancers in high-income countries are diagnosed while confined to the glans or foreskin; the disease is far commoner in parts of South America, Africa and Asia where circumcision is rare and HPV vaccination low.
- Subtypes: Penile intraepithelial neoplasia (PeIN, precursor; topical therapy, laser or circumcision); HPV-associated penile squamous cell carcinoma (basaloid, warty; p16 positive); HPV-independent penile squamous cell carcinoma (usual type, verrucous, sarcomatoid); Ta to T1 low-grade penile cancer (organ-sparing surgery, groin surveillance); T1 high-grade to T2 penile cancer with clinically negative groins (organ-sparing surgery plus sentinel node biopsy)
- Biomarkers: p16 immunohistochemistry and HPV DNA; Grade and lymphovascular invasion of the primary (decide sentinel node biopsy); Depth and stage (Ta, T1, T2) of the primary; Surgical margin status; Dynamic sentinel node biopsy result

## Sections of this record

The page is a hub with ten sections in reading order; large sections have their own page. The same plan as JSON: https://onco.cc/api/v1/cancers/localised-penile-cancer/sections.json

- Overview (on the hub): The TL;DR, the family this cancer belongs to, the organ, who gets it and what the state of the art is. https://onco.cc/cancers/localised-penile-cancer/#overview [3 state-of-the-art points]
- Types and stages (on the hub): Anatomy, the subtypes and how they differ, how it is staged, and where advanced disease spreads. https://onco.cc/cancers/localised-penile-cancer/#what-it-is [5 subtypes]
- Symptoms and diagnosis (on the hub): How this cancer shows itself, how the diagnosis is confirmed, and the biomarkers clinicians test for. https://onco.cc/cancers/localised-penile-cancer/#finding-it [5 biomarkers]
- Treatment (on the hub): The standard of care by setting, the medicines, surgery and radiotherapy named in it, and the regimens behind them. https://onco.cc/cancers/localised-penile-cancer/#treating-it [4 settings, 2 decisions with options]
- Trials and papers (on the hub): Trials recruiting now, the landmark trials, the trials held by this cancer's subtypes, the key papers and what they mean, the latest literature, and the milestones year by year. https://onco.cc/cancers/localised-penile-cancer/#evidence [1 trial, 2 key papers, 5 milestones]
- Biology and targets (on the hub): The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models. https://onco.cc/cancers/localised-penile-cancer/#science
- Countries and centres (own page): Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes. https://onco.cc/cancers/localised-penile-cancer/where-you-are/
- Decisions and support (on the hub): The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask. https://onco.cc/cancers/localised-penile-cancer/#living-with-it [16 questions, 3 red cards]
- Pipeline and open problems (own page): Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record. https://onco.cc/cancers/localised-penile-cancer/coming/ [2 medicines, 1 trial, 4 open problems]
- Data (own page): Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked. https://onco.cc/cancers/localised-penile-cancer/data/ [16 connected records]

## Standard of care

- Penile intraepithelial neoplasia: Circumcision if the foreskin is involved; topical fluorouracil or imiquimod, laser ablation or glans resurfacing; close follow-up because recurrence is common. ([Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Thermal ablation and cryotherapy for cervical precancer](https://onco.cc/technologies/precancer-ablation/))
- T1 to T2 tumours: Organ-sparing surgery (wide local excision, glansectomy, partial penectomy) with narrow margins; brachytherapy for small distal tumours; total penectomy only for large or proximal disease. ([Mohs surgery](https://onco.cc/terms/mohs-surgery/), [Brachytherapy](https://onco.cc/technologies/brachytherapy/))
- Clinically negative groins: Surveillance for low-risk tumours (Ta, T1 grade 1 without lymphovascular invasion); dynamic sentinel node biopsy for intermediate- and high-risk tumours, with inguinal lymphadenectomy if positive. ([Sentinel lymph node biopsy](https://onco.cc/technologies/sentinel-node/), [Lymphadenectomy (lymph node dissection)](https://onco.cc/terms/lymphadenectomy/))
- Prevention: HPV vaccination (now offered to boys in many countries and being tested in Chinese men) and treatment of phimosis and lichen sclerosus. ([HPV & HBV vaccination](https://onco.cc/technologies/hpv-vaccine/), [Nonavalent HPV vaccine](https://onco.cc/drugs/gardasil-9/), [A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males](https://onco.cc/trials/nct06465914/))

## State of the art

- Organ-sparing surgery with narrow margins is standard and preserves sexual and urinary function in most men.
- Dynamic sentinel node biopsy finds hidden groin metastases without the morbidity of prophylactic node dissection.
- Centralisation of care has improved outcomes in the United Kingdom and the Netherlands.

## Open problems

- Local recurrence after organ-sparing surgery is common and needs long follow-up.
- Sentinel node biopsy misses some metastases, and the false-negative rate depends on centre experience.
- Whether HPV status should change treatment is unknown.
- Most of the world's patients present late in places without specialist centres.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Penile_cancer
- EAU-ASCO penile cancer guideline 2023: https://doi.org/10.1016/j.eururo.2023.02.027
- Wikipedia: https://en.wikipedia.org/wiki/Penile_cancer

## Connected records

- cancers: [Localised anal squamous cell carcinoma (stage I to III)](https://onco.cc/cancers/localised-anal-cancer/), [Node-positive and metastatic penile cancer](https://onco.cc/cancers/node-positive-penile-cancer/), [Penile cancer](https://onco.cc/cancers/penile/)
- technologies: [Brachytherapy](https://onco.cc/technologies/brachytherapy/), [HPV & HBV vaccination](https://onco.cc/technologies/hpv-vaccine/), [Sentinel lymph node biopsy](https://onco.cc/technologies/sentinel-node/), [Thermal ablation and cryotherapy for cervical precancer](https://onco.cc/technologies/precancer-ablation/)
- drugs: [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Nonavalent HPV vaccine](https://onco.cc/drugs/gardasil-9/)
- terms: [HPV status (HPV-positive / HPV-negative)](https://onco.cc/terms/hpv-status/), [HPV-positive (p16) head and neck cancer](https://onco.cc/terms/hpv-p16/), [Lymphadenectomy (lymph node dissection)](https://onco.cc/terms/lymphadenectomy/), [Mohs surgery](https://onco.cc/terms/mohs-surgery/)
- trials: [A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males](https://onco.cc/trials/nct06465914/)
- key papers: [EAU-ASCO collaborative guideline on penile cancer, 2023 update](https://onco.cc/key-papers/paper-eau-asco-penile-cancer-guideline-eur-urol-2023/), [WHO classification of tumours of the urinary system and male genital organs, 2022: renal, penile and testicular tumours](https://onco.cc/key-papers/paper-who-2022-gu-moch-eur-urol-2022/)

---
JSON: https://onco.cc/api/v1/entities/localised-penile-cancer.json